Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
- Authors
- Jo, Jaemin; Kim, Jung Ho; Kim, Ji Young; Hyun, Changlim; Rhee, Jiyoung; Kwon, Jungmi; Han, Sanghoon; Kim, Wookun
- Issue Date
- Jan-2016
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Lung neoplasms; Drug therapy; Tyrosine kinase inhibitor; Pazopanib
- Citation
- CANCER RESEARCH AND TREATMENT, v.48, no.1, pp.393 - 397
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 48
- Number
- 1
- Start Page
- 393
- End Page
- 397
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8720
- DOI
- 10.4143/crt.2014.209
- ISSN
- 1598-2998
- Abstract
- Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8720)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.